Based on such metabolic regulatory benefits, DGAT1 or DGAT2 inhibitors, including PF-04620110 and Ervogastat (PF-06865571), have already been advanced to human Phase I-II clinical trials in healthy adults and individuals with non-alcoholic steatohepatitis or diabetes and demonstrated a significant reduction in postprandial TGs and liver fat percentage. Here, DGAT2 is linked to metabolic dysfunction-associated steatohepatitis.